Literature DB >> 19410688

IL-17-producing T cells in lung immunity and inflammation.

Chiara Nembrini1, Benjamin J Marsland, Manfred Kopf.   

Abstract

T(H)17 cells are a recently described effector CD4 T-cell subset characterized by the production of IL-17A, IL-17F, and IL-22, which have been implicated in the pathogenesis of several autoimmune diseases. T(H)17 and other IL-17A-producing T cells, including a population of gammadelta T cells and natural killer T cells, have also been associated with the development of skin, intestinal, and lung inflammatory diseases, such as asthma, granulomatous disease, chronic obstructive pulmonary disease, and cystic fibrosis. On the other hand, IL-17-producing T cells play important roles in protective immunity against some bacterial infections, mainly through the recruitment and activation of neutrophils. Thus, their regulation appears to be critical, and excess or deficient IL-17 elaboration leads either to deficient responses or disease. This review will summarize T(H)17 cell differentiation and discuss the host beneficial and detrimental function of IL-17A and related cytokines produced by different subpopulations of T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19410688     DOI: 10.1016/j.jaci.2009.03.033

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  76 in total

1.  B lymphocytes regulate airway granulocytic inflammation and cytokine production in a murine model of fungal allergic asthma.

Authors:  Sumit Ghosh; Scott A Hoselton; Scott V Asbach; Breanne N Steffan; Steve B Wanjara; Glenn P Dorsam; Jane M Schuh
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

2.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination.

Authors:  Chiara Nembrini; Armando Stano; Karen Y Dane; Marie Ballester; André J van der Vlies; Benjamin J Marsland; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

3.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

Review 4.  Innate and adaptive immune responses in asthma.

Authors:  Stephen T Holgate
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

5.  Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.

Authors:  Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

Review 6.  Importance of cytokines in murine allergic airway disease and human asthma.

Authors:  Fred D Finkelman; Simon P Hogan; Gurjit K Khurana Hershey; Marc E Rothenberg; Marsha Wills-Karp
Journal:  J Immunol       Date:  2010-02-15       Impact factor: 5.422

7.  Proinflammatory IL-17 induces iBALT development.

Authors:  Mingzhao Zhu; Yangxin Fu
Journal:  Cell Mol Immunol       Date:  2011-09-19       Impact factor: 11.530

8.  Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production.

Authors:  Benjamin J Murdock; Gary B Huffnagle; Michal A Olszewski; John J Osterholzer
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

9.  Pulmonary Interleukin-17-Positive Lymphocytes Increase during Pneumocystis murina Infection but Are Not Required for Clearance of Pneumocystis.

Authors:  Chiara Ripamonti; Lisa R Bishop; Joseph A Kovacs
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

Review 10.  Key mediators in the immunopathogenesis of allergic asthma.

Authors:  Sannette Hall; Devendra K Agrawal
Journal:  Int Immunopharmacol       Date:  2014-06-13       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.